MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Feb. 16, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its fourth quarter and fiscal year-end 2022 financial results on Thursday, February 23, 2023, at 8:30 AM Eastern time.
Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call to discuss the results as follows:
| Time | 8:30 A.M EST |
| Toll free (U.S.) | 1-833-630-1956 |
| International (U.S) | 1-412-317-1837 |
| Germany | 0800-6647650 |
| Israel | 1-80-9212373 |
| Access Code | Please ask to join into the ReWalk Robotics Ltd. call |
| Webcast (live and replay) | https://edge.media-server.com/mmc/p/z32t5emd under the ‘Investors’ section'. |
The archived webcast will be available via the following link https://edge.media-server.com/mmc/p/z32t5emd or through the 'Investors' section' on www.rewalk.com.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the Unites States.
Investor Contact:
Michael Lawless
Chief Financial Officer
ReWalk Robotics Ltd.
T: +1 508-281-7274
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.88 |
| Daily Change: | -0.13 -6.42 |
| Daily Volume: | 107,457 |
| Market Cap: | US$16.570M |
November 12, 2024 October 24, 2024 September 24, 2024 September 04, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
